Application and evaluation of Syndrome differentiation Xerox in chronic disease management of patients with advanced lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039904

Enrollment

Unknown

Registered

2020-11-14

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

The music group:Xerox syndrome differentiation, psychological support, conventional therapy

Control group:psychological support, conventional therapy

Eligibility

Sex/Gender

All

Age

45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 45-80 years old; 2. Patients meeting the diagnostic criteria of advanced lung cancer; 3. Patients who met the diagnostic criteria of anxiety state; 4. Patients meeting the diagnostic criteria of sleep disorders; 5. Subjects with informed consent signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious primary diseases or complications such as heart, liver, lung, kidney, etc; 2. Patients whose expected survival time is less than 6 months; 3. Patients who cannot cooperate with music therapy; 4. Patients who participated in any clinical trial within 30 days before screening; 5. Patients with any concomitant diseases that may interfere with the trial procedure or evaluation, or other conditions considered unsuitable by the researchers.

Design outcomes

Primary

Measure	Time frame
PSQI;SAS;CEA;KPS;	—

Countries

China

Contacts

Public ContactHuaxing Ji

Dongfang Hospital of Beijing University of traditional Chinese Medicine

kaluyimasi@163.com+86 15202209660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026